SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - September 2022

Sanofi: Information concerning the total number of voting rights and shares - September 2022

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,534,952,234 €

Registered office : 54, rue La Boétie - 75008 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date 



Total number of

issued shares



 
Number of real

voting rights

(excluding treasury shares)
Theoretical number of

voting rights

(including treasury shares)*
September 30, 20221,267,479,7661,411,899,2281,425,326,874

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

e-mail:



 



 

Attachment



EN
13/10/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press release: Sanofi successfully prices €1.5 billion bond issue

Press release: Sanofi successfully prices €1.5 billion bond issue   Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches:  €750 million fixed-rate notes, due June 2029, bearing interest at an annual rate of 2.625%.€750 million fixed-rate notes, due June 2032, bearing interest at an annual rate of 3.000%. The notes are being issued off the company's Euro Medium Term Note Programme. Sanofi intends to use the net proceeds of the offering for general corporat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch